-

Apollo Neuro Raises $15M Series A to Elevate the First Wellness Wearable That Actively Improves Mental Health

Round Led by Noetic Fund to Accelerate Growth as Category Leader in Wearable Stress Relief Technology

PITTSBURGH--(BUSINESS WIRE)--Apollo Neuro, makers of the first scientifically validated wearable that improves the body’s resilience to stress, today announced it has raised $15 million in Series A funding at a valuation over $100 million to empower people to take control of their mental health and well-being.

Led by Noetic Fund, the funding will help Apollo Neuro reach new global users who want to feel like a healthier, better version of themselves. Distinctively unique when compared to other wellness wearables that solely track health metrics, Apollo’s patented stress-relieving technology actively helps the body recover quickly, enabling better sleep, relaxation, and focus. Currently the Apollo wearable is available for a one time purchase ($349) in the United States, Canada, Europe and Australia/New Zealand, and pairs with a mobile app to help you transition throughout the day.

What is the Apollo wearable?

Apollo is a wellness wearable that improves your body’s resilience to stress, so you can relax, sleep, focus, recover, and feel better. Worn on either the wrist or ankle, the Apollo device works by engaging with your sense of touch, delivering silent, soothing vibrations that help you feel safe and in control. Apollo Neuro’s scientifically validated technology trains your nervous system to bounce back from stress more quickly, going from “fight or flight” to “rest and digest.”

Preliminary results from an ongoing sleep study (launched in 2021) showcase how the Apollo wearable improves the quality of sleep, along with important cardiovascular metrics including heart rate variability (HRV), a key metric of the body's recovery from and resilience to stress. The real-world study, featuring more than 500 participants, found that Apollo wearers experience, on average:

  • 19% increase in deep sleep
  • 14% increase in REM sleep
  • 5% lower resting heart rate
  • 11% average increase in heart rate variability (HRV)

“We are thrilled to announce the closing of our Series A, affording us the opportunity to rapidly accelerate advancements in consumer health with the Apollo wearable,” said Dr. David Rabin, Psychiatrist, Neuroscientist, and Co-Founder of Apollo Neuroscience. “Now, two years after bringing our product to market, we find ourselves living in a moment-in-time where Apollo Neuro’s scientifically proven stress-relieving technology is more vital than ever as we strive for more balance in our daily lives.”

Health Improvement, Not Health Tracking

By 2026, the global wearable technology market will exceed $19.12 billion with more than 344.9 million units shipping in 2022 alone. The Apollo wearable distinguishes itself in the category by showcasing the ability to improve health, while other wearable devices simply track health and data.

“Apollo Neuro’s touch technology represents an entirely new way to think about wearables,” said Co-Founder and CEO, Kathryn Fantauzzi. “Rather than tracking, Apollo Neuro’s gentle vibrations let us take control over how we feel so that we can focus, relax, get deep restorative sleep, or socialize. Now, with our Series A closed, we’re geared up and ready to deliver new ways to experience Apollo Neuro. I’m excited to show what’s possible when you tap into the sense of touch to enable us all to choose how we feel and experience the world around us.”

Developed by neuroscientists and physicians, the Apollo wearable is a safe, non-invasive stress relief tool for adults and children, without side effects. The Apollo device is a tool for mental health care and beneficial for anyone looking to incorporate active stress-relieving technology into their daily lives, from expectant moms to veterans to high-performance athletes to first responders, all of whom can benefit from consistent use.

Across the research, Apollo users (on average) experienced:

“At Noetic Fund we invest in innovative therapies that address significant unmet needs within mental health,'' said Sa’ad Shah, Co-Founder and Managing Partner at Noetic Fund. “Apollo Neuro represents a truly disruptive and scalable technology that makes managing stress, sleeping well, and keeping a clear mind easier. We’re excited by the potential of the Apollo wearable to complement new therapies, like psychedelic-assisted psychotherapy, and could not be more proud to partner with the Apollo Neuro team to present an accessible technology that is already changing tens of thousands of lives.”

About Apollo Neuro

Apollo Neuroscience is pioneering new ways to improve mental health by addressing the root of stress and anxiety, the nervous system. The Apollo wearable uses touch therapy to strengthen and rebalance the nervous system, actively improving the body’s resilience to stress. Worn on the wrist or ankle, Apollo's scientifically validated technology sends gentle vibrations to the body that help you feel safe and in control. It’s a simple, unobtrusive tool that trains the nervous system to recover from stress more effectively, without effort on the part of the user. The result? Less stress, more sleep. Less fatigue, more focus. The Apollo wearable is safe for adults and children alike, without side effects. Developed by physicians and neuroscientists, Apollo has been tested in multiple studies and clinical trials and is proven to improve heart rate variability (HRV), a key biometric of stress resilience. For more information, visit apolloneuro.com.

Contacts

Jack Taylor PR
Izzy Evans
e: apolloneuro@jacktaylorpr.com
p: 586.864.0903

Apollo Neuro


Release Versions

Contacts

Jack Taylor PR
Izzy Evans
e: apolloneuro@jacktaylorpr.com
p: 586.864.0903

Social Media Profiles
More News From Apollo Neuro

Apollo Neuroscience Initiates IRB-Approved Clinical Trial Series to Understand Effectiveness of the Apollo Wearable for Treatment of PTSD

PITTSBURGH--(BUSINESS WIRE)--Apollo NeuroscienceTM, makers of the first scientifically-validated wearable that improves the body’s resilience to stress, is running an IRB-approved clinical trial with the support of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit sponsoring the most advanced clinical trials of a psychedelic-assisted therapy. The purpose of this study is to understand how the Apollo Neuro™ proprietary wearable touch therapy device impacts long-term o...

Apollo Neuro and the NFL Alumni Association Announce Multi-Year Partnership

PITTSBURGH--(BUSINESS WIRE)--Apollo NeuroscienceTM, makers of the first scientifically-validated wearable that improves the body’s resilience to stress, today announced a multi-year partnership with the National Football League Alumni Association (NFLAA), the oldest, most well-known and well-respected retired player organization in professional sports. The partnership is a result of ongoing conversations the NFLAA has had with its community looking for better tools for safely improving sleep, p...

Apollo Neuroscience Names Alan Cannistraro Chief Technology Officer

PITTSBURGH--(BUSINESS WIRE)--Apollo Neuroscience, makers of Apollo™, a new category of wearable technology that actively improves health, today announced the hiring of Alan Cannistraro as Chief Technology Officer (CTO). The Apollo device is the first scientifically validated wellness wearable to actively improve sleep, resilience to stress, focus, and calm. During Cannistraro’s twelve year tenure at Apple, beginning in 2000, he created an impressive roster of software applications while working...
Back to Newsroom